Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richetta

Showing results (201-210 of 233) with videos related to

Pageof 24
Sort By:
Dermatology Practical & Conceptual|March 21, 2025
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in ItalyFederico Pirro, Giacomo Caldarola, Nicoletta Bernardini, et al.
Clinical Drug Investigation|July 1, 2010
Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuationAnnalisa Arcese, Nicola Aste, Alberta Bettacchi, et al.
Dermatology Practical & Conceptual|April 14, 2025
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio ExperienceAnnunziata Dattola, Nicoletta Bernardini, Elena Campione, et al.
Plos Pathogens|December 17, 2011
IRGM is a common target of RNA viruses that subvert the autophagy networkIsabel Pombo Grégoire, Clémence Richetta, Laurène Meyniel-Schicklin, et al.
The Journal of Dermatological Treatment|February 27, 2024
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Clinics and Practice|March 27, 2026
Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the LegsAnnunziata Dattola, Raimondo Rossi, Giuseppe Rizzuto, et al.
Patient Preference and Adherence|November 26, 2021
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in ItalyGiuseppe Argenziano, Paolo Amerio, Maria Grazia Aragone, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|November 25, 2025
The management of pediatric Chiari I malformation with concomitant hydrocephalus: a multicenter retrospective analysisLadina Greuter, Tim Jonas Hallenberger, Maria Licci, et al.
Pageof 24

Showing results (201-210 of 233) with videos related to

Sort By:
Pageof 24
Dermatology Practical & Conceptual|March 21, 2025
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in ItalyFederico Pirro, Giacomo Caldarola, Nicoletta Bernardini, et al.
Clinical Drug Investigation|July 1, 2010
Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuationAnnalisa Arcese, Nicola Aste, Alberta Bettacchi, et al.
Dermatology Practical & Conceptual|April 14, 2025
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio ExperienceAnnunziata Dattola, Nicoletta Bernardini, Elena Campione, et al.
Plos Pathogens|December 17, 2011
IRGM is a common target of RNA viruses that subvert the autophagy networkIsabel Pombo Grégoire, Clémence Richetta, Laurène Meyniel-Schicklin, et al.
The Journal of Dermatological Treatment|February 27, 2024
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Clinics and Practice|March 27, 2026
Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the LegsAnnunziata Dattola, Raimondo Rossi, Giuseppe Rizzuto, et al.
Patient Preference and Adherence|November 26, 2021
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in ItalyGiuseppe Argenziano, Paolo Amerio, Maria Grazia Aragone, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|November 25, 2025
The management of pediatric Chiari I malformation with concomitant hydrocephalus: a multicenter retrospective analysisLadina Greuter, Tim Jonas Hallenberger, Maria Licci, et al.
Pageof 24